Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I5HE
|
|||
| Former ID |
DPR000082
|
|||
| Drug Name |
NPY5RA-972
|
|||
| Synonyms |
NPY 5RA972; 439861-56-0; CHEMBL325226; N-[4-METHYL-9-(1-METHYLETHYL)-9H-CARBAZOL-3-YL]-4-MORPHOLINECARBOXAMIDE; SCHEMBL6826732; CTK8F0016; DTXSID30432395; MolPort-023-276-896; ZINC27101553; BDBM50116592; AKOS024457744; NCGC00370914-01; RT-014756; B7466; N-(4-Methyl-9-isopropyl-9H-carbazole-3-yl)morpholine-4-carboxamide; Morpholine-4-carboxylic acid (9-isopropyl-4-methyl-9H-carbazol-3-yl)-amide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Preclinical | [1] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H25N3O2
|
|||
| Canonical SMILES |
CC1=C(C=CC2=C1C3=CC=CC=C3N2C(C)C)NC(=O)N4CCOCC4
|
|||
| InChI |
1S/C21H25N3O2/c1-14(2)24-18-7-5-4-6-16(18)20-15(3)17(8-9-19(20)24)22-21(25)23-10-12-26-13-11-23/h4-9,14H,10-13H2,1-3H3,(H,22,25)
|
|||
| InChIKey |
ZNFMHLDBJPAFEQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 439861-56-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuropeptide Y receptor type 5 (NPY5R) | Target Info | Antagonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.